These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2834044)

  • 1. High-dose cisplatin-related peripheral neuropathy.
    Ostchega Y; Donohue M; Fox N
    Cancer Nurs; 1988 Feb; 11(1):23-32. PubMed ID: 2834044
    [No Abstract]   [Full Text] [Related]  

  • 2. Cisplatin dose intensity.
    Ozols RF
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):22-30. PubMed ID: 2669135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients.
    Panici PB; Greggi S; Scambia G; Di Roberto P; Iacobelli S; Mancuso S
    Cancer Treat Rep; 1987 Jun; 71(6):669-70. PubMed ID: 3034424
    [No Abstract]   [Full Text] [Related]  

  • 4. Peripheral neuropathy secondary to cis-Dichlorodiammino-platinum (II) (Platinol). Treatment for advanced ovarian cancer.
    Marin AC; Rierson B
    Ariz Med; 1979 Dec; 36(12):898-9. PubMed ID: 229809
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
    Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
    Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin: an anti-tumour agent.
    Drug Ther Bull; 1979 Dec; 17(25):99-100. PubMed ID: 575631
    [No Abstract]   [Full Text] [Related]  

  • 8. Platinum dose-intensity in solid tumors: pharmacological and clinical perspectives.
    Pagani O; Sessa C; Cavalli F
    Bull Cancer; 1995; 82 Suppl 1():16s-23s. PubMed ID: 7626849
    [No Abstract]   [Full Text] [Related]  

  • 9. Cisplatin (Platinol).
    Med Lett Drugs Ther; 1979 Apr; 21(8):33-4. PubMed ID: 431486
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cisplatin polyneuropathy].
    Beghi E; Bogliun G; Crespi V; Delodovici ML; Landoni F
    Riv Neurobiol; 1984; 30(2-3):431-7. PubMed ID: 6100526
    [No Abstract]   [Full Text] [Related]  

  • 11. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.
    Argyriou AA; Chroni E; Koutras A; Ellul J; Papapetropoulos S; Katsoulas G; Iconomou G; Kalofonos HP
    Neurology; 2005 Jan; 64(1):26-31. PubMed ID: 15642899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of cisplatin nephrotoxicity in cancer: adjusting the dosage with a computerized chrono-pump].
    Gestin-Boyer C; René C; Cupissol D; Tep A; Bressolle F; Bres J; Brun S; Serrou B; Pujol H
    C R Seances Soc Biol Fil; 1989; 183(3):263-8. PubMed ID: 2532561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
    J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Delayed platinum diamminodichloride toxicity in patients with germ tumors of the gonads].
    Germà Lluch JR; Izquierdo Font A; Barnadas Molins A; Arcusa Lanza MA; Ojeda González B
    Med Clin (Barc); 1984 Mar; 82(10):442-5. PubMed ID: 6538917
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epileptic seizures associated with cisplatin administration.
    Mead GM; Arnold AM; Green JA; Macbeth FR; Williams CJ; Whitehouse JM
    Cancer Treat Rep; 1982 Sep; 66(9):1719-22. PubMed ID: 6889460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.
    Krarup-Hansen A; Helweg-Larsen S; Schmalbruch H; Rørth M; Krarup C
    Brain; 2007 Apr; 130(Pt 4):1076-88. PubMed ID: 17301082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuropathy caused by cisplatin. 7 cases including one with an autopsy study].
    Amiel H; Gherardi R; Giroux C; Salama J; Bréau JL; Delaporte P
    Ann Med Interne (Paris); 1987; 138(2):96-100. PubMed ID: 3034113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
    Chaudhry V; Rowinsky EK; Sartorius SE; Donehower RC; Cornblath DR
    Ann Neurol; 1994 Mar; 35(3):304-11. PubMed ID: 7907208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.